DE3579146D1 - Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung. - Google Patents

Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung.

Info

Publication number
DE3579146D1
DE3579146D1 DE8585116670T DE3579146T DE3579146D1 DE 3579146 D1 DE3579146 D1 DE 3579146D1 DE 8585116670 T DE8585116670 T DE 8585116670T DE 3579146 T DE3579146 T DE 3579146T DE 3579146 D1 DE3579146 D1 DE 3579146D1
Authority
DE
Germany
Prior art keywords
stabilized
cancer
spergualin
medicinal products
containing medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585116670T
Other languages
German (de)
English (en)
Inventor
Hamao Prof Umezawa
Shintaro Suzuki
Takaaki Okuma
Fumihiro Sato
Teruya Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Application granted granted Critical
Publication of DE3579146D1 publication Critical patent/DE3579146D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DE8585116670T 1985-01-14 1985-12-31 Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung. Expired - Lifetime DE3579146D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60003351A JPS61165322A (ja) 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤

Publications (1)

Publication Number Publication Date
DE3579146D1 true DE3579146D1 (de) 1990-09-13

Family

ID=11554927

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585116670T Expired - Lifetime DE3579146D1 (de) 1985-01-14 1985-12-31 Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung.

Country Status (10)

Country Link
US (2) US4710517A (enExample)
EP (1) EP0188821B1 (enExample)
JP (1) JPS61165322A (enExample)
KR (1) KR920003331B1 (enExample)
CN (1) CN1010279B (enExample)
AT (1) ATE55246T1 (enExample)
AU (1) AU589939B2 (enExample)
CA (1) CA1263316A (enExample)
DE (1) DE3579146D1 (enExample)
IE (1) IE58220B1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61129119A (ja) * 1984-11-13 1986-06-17 Microbial Chem Res Found 新規免疫抑制剤
EP0241797B1 (en) * 1986-04-04 1991-06-12 Microbial Chemistry Research Foundation Novel spergualin-related compounds and process for producing the same
FR2622104B1 (fr) * 1987-10-22 1990-03-30 Bioetica Sa Procede de stabilisation de phases lamellaires lipidiques hydratees, par ex. de liposomes, composition de phases lamellaires lipidiques hydratees, par ex. des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes et utilisation en pharmacie ou en cosmetologie
CA1330650C (fr) * 1987-10-22 1994-07-12 Alain Huc Procede de stabilisation de phases lamellaires lipidiques hydratees, par exemple de liposomes, composition de phases lamellaires lipidiques hydratees, par exemple des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes, et utilisation en pharmacie ou en ...
EP0398925B1 (en) * 1988-01-19 1993-10-20 Children's Hospital Corporation Growth inhibiting agent and the use thereof
AU626538B2 (en) * 1988-01-19 1992-08-06 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5002756A (en) * 1988-04-04 1991-03-26 Zaidanhojin Biseibutsu Kagakukenkyukai Method for relieving radiogenic or drug-induced side effects
ATE78156T1 (de) * 1988-12-02 1992-08-15 Coletica Stabilisierung von hydratierten lamellaren phasen.
CA2028848A1 (en) * 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
US5424301A (en) * 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
CA2159717A1 (en) * 1993-03-31 1994-10-13 Elliot Barnathan Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
CA2183917A1 (en) * 1995-09-26 1997-03-27 Xuebao Wang Preparation of optically active (s)-(-) and (r)-(+)- deoxyspergualin and novel intermediates thereof
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
ES2210769T3 (es) * 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54157818A (en) * 1978-06-02 1979-12-13 Tokyo Tanabe Co Injectionable preparation of chlorethylnitrosourea compound
JPS5748957A (en) * 1980-09-08 1982-03-20 Microbial Chem Res Found Novel antibiotic bmg 162-af2, its preparation and carcinostatic agent comprising it as active ingredient
JPS57185254A (en) * 1981-05-11 1982-11-15 Microbial Chem Res Found Novel carcinostatic substances and their preparation
JPS5862152A (ja) * 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
JPS58198455A (ja) * 1982-05-17 1983-11-18 Microbial Chem Res Found （−）−１５−デオキシスパガリンおよびその製造法並びにその中間体
JPS5942356A (ja) * 1982-09-02 1984-03-08 Microbial Chem Res Found スパガリン関連化合物およびその製造法
US4525299A (en) * 1983-05-10 1985-06-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (-)-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same
JPS60185758A (ja) * 1984-03-02 1985-09-21 Microbial Chem Res Found フエニレン基を有するスパガリン関連化合物およびその製造法

Also Published As

Publication number Publication date
EP0188821A3 (en) 1987-08-12
EP0188821A2 (en) 1986-07-30
ATE55246T1 (de) 1990-08-15
JPH0413325B2 (enExample) 1992-03-09
KR920003331B1 (ko) 1992-04-27
IE58220B1 (en) 1993-08-11
US4710517A (en) 1987-12-01
AU5222486A (en) 1986-07-17
EP0188821B1 (en) 1990-08-08
CN86100157A (zh) 1986-08-27
CN1010279B (zh) 1990-11-07
AU589939B2 (en) 1989-10-26
US4876244A (en) 1989-10-24
JPS61165322A (ja) 1986-07-26
KR860005636A (ko) 1986-08-11
IE860089L (en) 1986-07-14
CA1263316A (en) 1989-11-28

Similar Documents

Publication Publication Date Title
ATE55246T1 (de) Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
DE68914365D1 (de) Topische metronidazol-formulationen und deren verwendung als arzneimittel.
NL193981B (nl) 7-(eventueel gesubstitueerd naftyl)-3-methyl-octa-2,4,6-trieenderivaten met retineachtige werking alsmede farmaceutische en kosmetische preparaten die dergelijke derivaten bevatten.
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
OA09458A (en) Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
ATE99302T1 (de) Substituierte flavonoide verbindungen, ihre salze, ihre herstellung und die enthaltende arnzeizusammensetzungen.
KR930701456A (ko) 세팔로스포린 및 동족체, 제조 및 제약학적 조성물
DE59010536D1 (de) Diphenylheteroalkylderivate, ihre Herstellung und daraus hergestellte Arzneimittel und Kosmetika
DK0559018T3 (da) Taxanderivater, deres fremstilling og anvendelse indenfor onkologi
MX18106A (es) Compuesto amidinicos y composiciones usadas para el tratamiento de pneumonia por pneumocystis carinii y otras enfermedades.
EP0217748A3 (en) 2-substituted-e-fused-û1,2,4,¨triazolo-û1,5-c¨pyrimidines pharmaceutical compositions and uses thereof
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
BR9205642A (pt) Composiçao farmacêutica, compreendo pelo menos uma quinona, e composiçao para fabricaçao de medicamento
DK0437225T3 (da) Topiske præparater
ATE88629T1 (de) Kosmetische un paramedizinische praeparate.
IT8322486A0 (it) N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
IT8922175A0 (it) Derivati amminici di 2,3-diaza-antracene-9,10-dioni come farmaci antitumorali
ITRM920930A0 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.
ATE47863T1 (de) Makrolide derivate.
IT1230053B (it) Composizione per l'aumento del guadagno di peso.
MX9203581A (es) Composiciones farmaceuticas de indolinas 3,3-disubstituidas, para administracion nasal.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee